Novartis Reports New Data of Kesimpta (ofatumumab) in ALITHIOS Study for Multiple Sclerosis
Shots:
- The ongoing OLE of ALITHIOS study involves assessing Kesimpta in 1-703 patients with MS for ~5 yrs which showed mean IgG levels remained unchanged @ 3.5 yrs & mean IgM levels remained within the reference range with no increased risk of infections
- Additionally- the results were consistent with P- III ASCLEPIOS trials data which showed a low incidence of infections & no association was identified b/w decreased Ig levels & risk of serious infections & was a well-tolerated treatment option for patients with RMS
- Kesimpta is a targeted B-cell therapy while results are presented at EAN 2021 with other wide-ranging data to understand the impact of the immune response toward vaccinations
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com